POD24 rate and impact on survival
| . | Regimens . | Type of study . | No. of patients . | POD24 . | Survival . |
|---|---|---|---|---|---|
| National LymphoCare Prospective Observational Study1 | R-CHOP | Retrospective | 588 | POD24: 19% (n = 110) No POD24: 71% (n = 420) | 5-y OS: 50% vs 90% |
| Jurinovic et al3 | R-CHOP followed by IFN-α maintenance R-CVP followed by R-maintenance | Clinical trial (GLSG2000 trial; n = 151) and population-based registry (BCCA; n = 107) | 258 | GLSG - POD24: 17% (n = 23) No POD24: 83% (n = 109) BCCA - POD24: 23% (n = 23) No POD24: 77% (n = 79) | GLSG - 5-y OS: 41% vs 91% BCCA - 5-y OS: 26% vs 86% |
| Weillbull et al4 | R-chemo (R-CHOP, n = 308; BR, n = 150, R-CVP, n = 45; R-FC, n = 16), R-mono (n = 273), Others (n = 156) | Population-based registry (Swedish Lymphoma Register) | 948 | R-chemo - POD24: 61% (n = 110) No POD24: 39% (n = 69) R-mono - POD24: 68% (n = 113) No POD24: 32% (n = 52) | R-chemo - 5-y OS: 46% vs 82% R-mono - 5-y OS: 73% vs 85% |
| Casulo et al5 | 10 induction R-chemo and 3 maintenance randomized trials | Clinical trials | 5225 | POD24: 29% (n = 1531) No POD24: 68% (n = 3564) | 3-y OS: 87% vs 98% 5-y OS: 71% vs 93% |
| Seymour et al6 | R- vs O-CHOP/BR | Clinical trial (GALLIUM trial) | 1202 | POD24: 13% (n = 155) No POD24: 76% (n = 916) | 2-y OS: 82% vs 98% |
| CALGB trials7 | R-galiximab, R-epratuzumab, R-lenalidomide | Clinical trials (CALGB 50402, CALGB 50701, CALGB 50803) | 174 | POD24: 28% (n = 48) No POD24: 72% (n = 126) | 2-y OS: 80% vs 99% 5-y OS: 74% vs 90% |
| Freeman et al8 | BR followed by R-maintenance | Population-based registry (BCCA) | 296 | POD24: 13% (n = 37) | 2-y OS: 38% |
| . | Regimens . | Type of study . | No. of patients . | POD24 . | Survival . |
|---|---|---|---|---|---|
| National LymphoCare Prospective Observational Study1 | R-CHOP | Retrospective | 588 | POD24: 19% (n = 110) No POD24: 71% (n = 420) | 5-y OS: 50% vs 90% |
| Jurinovic et al3 | R-CHOP followed by IFN-α maintenance R-CVP followed by R-maintenance | Clinical trial (GLSG2000 trial; n = 151) and population-based registry (BCCA; n = 107) | 258 | GLSG - POD24: 17% (n = 23) No POD24: 83% (n = 109) BCCA - POD24: 23% (n = 23) No POD24: 77% (n = 79) | GLSG - 5-y OS: 41% vs 91% BCCA - 5-y OS: 26% vs 86% |
| Weillbull et al4 | R-chemo (R-CHOP, n = 308; BR, n = 150, R-CVP, n = 45; R-FC, n = 16), R-mono (n = 273), Others (n = 156) | Population-based registry (Swedish Lymphoma Register) | 948 | R-chemo - POD24: 61% (n = 110) No POD24: 39% (n = 69) R-mono - POD24: 68% (n = 113) No POD24: 32% (n = 52) | R-chemo - 5-y OS: 46% vs 82% R-mono - 5-y OS: 73% vs 85% |
| Casulo et al5 | 10 induction R-chemo and 3 maintenance randomized trials | Clinical trials | 5225 | POD24: 29% (n = 1531) No POD24: 68% (n = 3564) | 3-y OS: 87% vs 98% 5-y OS: 71% vs 93% |
| Seymour et al6 | R- vs O-CHOP/BR | Clinical trial (GALLIUM trial) | 1202 | POD24: 13% (n = 155) No POD24: 76% (n = 916) | 2-y OS: 82% vs 98% |
| CALGB trials7 | R-galiximab, R-epratuzumab, R-lenalidomide | Clinical trials (CALGB 50402, CALGB 50701, CALGB 50803) | 174 | POD24: 28% (n = 48) No POD24: 72% (n = 126) | 2-y OS: 80% vs 99% 5-y OS: 74% vs 90% |
| Freeman et al8 | BR followed by R-maintenance | Population-based registry (BCCA) | 296 | POD24: 13% (n = 37) | 2-y OS: 38% |
IFN-α, interferon alfa; O-CHOP, obinutuzumab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CVP, rituximab-cyclophosphamide- vincristine-prednisone; R-FC, rituximab, fludarabine, and cyclophosphamide; R-mono, rituximab monotherapy.